Results 11 to 20 of about 2,622 (185)

Impact of filgotinib on pain control in the phase 3 FINCH studies [PDF]

RMD Open
Objective This post hoc analysis of the FINCH 1–3 (NCT02889796, NCT02873936 and NCT02886728) studies assessed specific effects of filgotinib on pain control and their relationship with other aspects of efficacy in patients with rheumatoid arthritis (RA).
Bruno Fautrel, Peter Nash, Arthur Kavanaugh, Peter C Taylor, René Westhovens, Rieke Alten, Janet Pope, Dick de Vries, Chris Watson, Georg Pongratz, Pieter-Jan Stiers, Ken Hasegawa, Shangbang Rao   +12 more
doaj   +8 more sources

The Role of Filgotinib in Ulcerative Colitis and Crohn’s Disease [PDF]

Immunotherapy, 2023
Filgotinib is an oral small molecule that selectively inhibits JAK1. It is already approved for the treatment of moderately to severely active ulcerative colitis (UC). Ongoing studies are evaluating the efficacy and safety of filgotinib in Crohn's disease (CD).
Fanizza J, D'Amico F, Lauri G, Martinez-Dominguez SJ, Allocca M, Furfaro F, Zilli A, Fiorino G, Parigi TL, Radice S, Peyrin-Biroulet L, Danese S   +11 more
openaire   +4 more sources

Evaluating filgotinib for the treatment of rheumatoid arthritis [PDF]

Expert Opinion on Pharmacotherapy, 2021
Despite the availability of an extensive armamentarium, rheumatoid arthritis (RA) remains a therapeutic challenge for rheumatologists. Janus kinase inhibitors (JAKi) are an emerging class of targeted therapies. The number of JAKi has been growing and to date, filgotinib is the latest JAKi to be approved for use in RA.This review focuses on the ...
Christophe Richez, Marie-Elise Truchetet
openaire   +3 more sources

Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy [PDF]

RMD Open, 2020
Objectives Patients with lupus membranous nephropathy (LMN) are at risk for prolonged proteinuria and progressive chronic kidney disease. There are no proven effective treatments for LMN, and controlled trials are lacking.
Sam Lim, Matthew Baker, Vimal Derebail, Yashaar Chaichian, Mark Genovese, Panduranga Rao, Winn Chatham, Michael Bubb, Hooman Hajian, Oksana Gurtovaya, Uptal Patel, James Tumlin   +11 more
doaj   +2 more sources

Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate [PDF]

Rheumatology and Therapy, 2023
Introduction Our aim was to evaluate protein biomarker changes related to the administration of filgotinib, a Janus kinase (JAK) 1 preferential inhibitor, in patients with moderately to severely active rheumatoid arthritis (RA) with inadequate response ...
Yoshiya Tanaka, Peter C. Taylor, Emon Elboudwarej, Angie Hertz, Xiaorong Shao, Vladislav A. Malkov, Hironori Matsushima, Kahaku Emoto, Bryan Downie, Tsutomu Takeuchi   +9 more
doaj   +3 more sources

The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies [PDF]

Arthritis Research & Therapy, 2022
Background The effects of filgotinib on patient-reported outcomes (PROs) from 3 trials in patients with active rheumatoid arthritis were investigated.
Clifton O. Bingham, David Walker, Peter Nash, Susan J. Lee, Lei Ye, Hao Hu, Javaria Mona Khalid, Bernard Combe   +7 more
doaj   +2 more sources

Real-world assessment of effectiveness and safety of filgotinib in 286 patients with ulcerative colitis in 9 UK centres [PDF]

Drugs in Context
Background: Filgotinib, an oral Janus kinase 1 preferential inhibitor, has been shown to be an effective treatment for ulcerative colitis (UC) in pre-registration studies.
David Young, Sohail Rahmany, Deborah Taylor, Emma Davis, Michael Colwill, Sonia Kalyanji Mehta, Roisin Campbell, Karl Hazel, Karishma Sethi-Arora, Susan Ritchie, Ashley I Heinson, Helen Moyses, Keith Bodger, Emma Johnston, Lucy Hicks, Anjan Dhar, Jimmy Limdi, Rachel Cooney, John Paul Seenan, Kamal Patel, Alissa Walsh, Fraser Cummings   +21 more
doaj   +3 more sources

Validated DBS method for filgotinib quantitation in rat dried blood spots and its application to a pharmacokinetic study in rats [PDF]

ADMET and DMPK, 2020
Filgotinib is a selective JAK1 (Janus kinase) inhibitor, showed efficacy in patients suffering from moderate-to-severe rheumatoid arthritis. In this paper, we present the data on the development and validation of a sensitive, selective and high ...
Abhishek Dixit, Vinay Kiran, Bhavesh Babulal Gabani, Ramesh Mullangi   +3 more
doaj   +3 more sources

Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes [PDF]

Arthritis Research & Therapy, 2018
Background The aim was to assess patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) treated with filgotinib during two phase 2b, 24-week, randomized, placebo-controlled studies.
Mark Genovese, Rene Westhovens, Luc Meuleners, Annegret Van der Aa, Pille Harrison, Chantal Tasset, Arthur Kavanaugh   +6 more
doaj   +2 more sources

Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study [PDF]

RMD Open
Objectives DARWIN 3 (ClinicalTrials.gov: NCT02065700) assessed the safety and efficacy of filgotinib in a long-term extension (LTE) of two phase II randomised controlled rheumatoid arthritis (RA) trials.Methods Eligible patients completing the 24-week ...
Arthur Kavanaugh, Paul Emery, René Westhovens, Mark C Genovese, Kevin L Winthrop, Rieke Alten, Dick de Vries, Lorenzo Dagna, Patrick Verschueren, Maria Greenwald, Regina Cseuz, Robin Besuyen, Vikas Modgill, Ly Huong Le   +13 more
doaj   +3 more sources